News & Events: 2016

Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

December 21, 2016
  Collaboration designed to leverage Merus' Biclonics® bispecific antibody technology to expand Incyte's discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 mi...
Read more

ISA Pharmaceuticals Advances Personalized Cancer Treatment

December 07, 2016
- Next-generation immunotherapy called MyISA® for individual cancer patients Leiden, The Netherlands, December 7, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the re...
Read more

ISA Pharmaceuticals Appoints Bart Bergstein as Chairman of the Supervisory Board

June 03, 2016
Leiden, The Netherlands, June 03, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, to...
Read more

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

June 01, 2016
Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology BERLIN & UTRECHT, The Netherlands, June  01, 2016  (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today join...
Read more

Merus N.V. Announces Closing of Initial Public Offering

May 25, 2016
UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus") (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offer...
Read more

Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML

May 04, 2016
Posted on 4 May, 2016 UTRECHT, The Netherlands (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that th...
Read more

ISA Pharmaceuticals obtains broad patent protection in the US for proprietary AMPLIVANT® platform and compounds

April 21, 2016
- Granted US patent provides market exclusivity until 2032 - Leiden, The Netherlands, April 19, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immu...
Read more

Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting

April 18, 2016
Posted on 18 April, 2016 MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE)...
Read more

ISA Pharmaceuticals' Lead Product ISA101 Efficiently Engages the Immune System Against Virus-Induced Pre-malignant and Malignant Lesions

April 15, 2016
• ISA101 clinically effective against HPV-induced vulvar / vaginal lesions and cervical cancer • Optimum immunotherapy window in cancer identified Leiden, The Netherlands, April 14, 2016 - ISA Pharmaceu...
Read more

ORCA Therapeutics raises €1.5 million for funding non clinical evaluation and GMP production of their lead product ORCA-010

April 01, 2016
NIJMEGEN, 01 - 04 - 2016 ORCA Therapeutics B.V. raises € 1.5 Million for the non clinical evaluation and GMP production of t...
Read more
ORCA Therapeutics raises €1.5 million for funding non clinical evaluation and GMP production of their lead product ORCA-010

Scientific Review Endorses ISA Pharmaceuticals’ Strategy to Overcome Immune Evasion in Cancer Immunotherapy

March 11, 2016
- Targeting and Activating Dendritic Cells is the Key to Success Leiden, The Netherlands, March 11, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has announced the publication o...
Read more

Merus Announces Issuance of Three U.S. Patents Strengthening its Biclonics® Technology Platform for the Discovery and Manufacturing of Human Bispecific Antibodies

March 10, 2016
Utrecht, The Netherlands, March 9, 2016 -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Tradem...
Read more

Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications

January 05, 2016
UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gus...
Read more

ISA Pharmaceuticals Appoints Gerben Moolhuizen as Chief Business Development Officer

January 05, 2016
•    Seasoned executive brings over twenty years of commercial biotech and pharma experience Leiden, The Netherlands, January 5, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company foc...
Read more

Home > News & Events > Archive

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds